Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Slim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Francois Lefebvre, Mark Cameron, J. Kaewkungwal, P. Pitisuttithum, S. Nitayaphan, S. Rerks-Ngarm, Jerome H. Kim, Rasmi Thomas, Peter B. Gilbert, Georgia D. Tomaras, Richard A. Koup, Nelson L. Michael, M. Juliana McElrath, Raphael Gottardo, Rafick-Pierre Sékaly
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2019
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/39e0d85840e44cd7872a97b96a0ffad9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Documents similaires